198 related articles for article (PubMed ID: 29935374)
21. mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation.
Alayev A; Salamon RS; Berger SM; Schwartz NS; Cuesta R; Snyder RB; Holz MK
Oncogene; 2016 Jul; 35(27):3535-43. PubMed ID: 26522726
[TBL] [Abstract][Full Text] [Related]
22. RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
Thaler S; Schmidt M; Schad A; Sleeman JP
Oncogene; 2012 Nov; 31(47):4912-22. PubMed ID: 22266866
[TBL] [Abstract][Full Text] [Related]
23. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.
Morrison MM; Williams MM; Vaught DB; Hicks D; Lim J; McKernan C; Aurisicchio L; Ciliberto G; Simion C; Sweeney C; Cook RS
Oncogene; 2016 Mar; 35(9):1143-52. PubMed ID: 26148232
[TBL] [Abstract][Full Text] [Related]
24. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
[TBL] [Abstract][Full Text] [Related]
25. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs.
Guttilla IK; Phoenix KN; Hong X; Tirnauer JS; Claffey KP; White BA
Breast Cancer Res Treat; 2012 Feb; 132(1):75-85. PubMed ID: 21553120
[TBL] [Abstract][Full Text] [Related]
26. PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
Citro S; Miccolo C; Meloni L; Chiocca S
J Mol Cell Biol; 2015 Apr; 7(2):132-42. PubMed ID: 25801958
[TBL] [Abstract][Full Text] [Related]
27. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
28. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
29. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt.
Lai Y; Yu X; Lin X; He S
Int J Mol Med; 2016 Feb; 37(2):369-77. PubMed ID: 26707081
[TBL] [Abstract][Full Text] [Related]
31. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
32. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
[TBL] [Abstract][Full Text] [Related]
33. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
34. COX-2 modulates mammary tumor progression in response to collagen density.
Esbona K; Inman D; Saha S; Jeffery J; Schedin P; Wilke L; Keely P
Breast Cancer Res; 2016 Mar; 18(1):35. PubMed ID: 27000374
[TBL] [Abstract][Full Text] [Related]
35. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
37. In Vivo Evidence for Serine Biosynthesis-Defined Sensitivity of Lung Metastasis, but Not of Primary Breast Tumors, to mTORC1 Inhibition.
Rinaldi G; Pranzini E; Van Elsen J; Broekaert D; Funk CM; Planque M; Doglioni G; Altea-Manzano P; Rossi M; Geldhof V; Teoh ST; Ross C; Hunter KW; Lunt SY; Grünewald TGP; Fendt SM
Mol Cell; 2021 Jan; 81(2):386-397.e7. PubMed ID: 33340488
[TBL] [Abstract][Full Text] [Related]
38. Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling.
Madak-Erdogan Z; Band S; Zhao YC; Smith BP; Kulkoyluoglu-Cotul E; Zuo Q; Santaliz Casiano A; Wrobel K; Rossi G; Smith RL; Kim SH; Katzenellenbogen JA; Johnson ML; Patel M; Marino N; Storniolo AMV; Flaws JA
Cancer Res; 2019 May; 79(10):2494-2510. PubMed ID: 30862719
[TBL] [Abstract][Full Text] [Related]
39. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
40. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura A; Lawrence J; Berstein L; Yue W
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S61-73. PubMed ID: 16113100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
